Program in Bioethics.
Institute for Health & Aging.
Clin Obstet Gynecol. 2021 Dec 1;64(4):933-940. doi: 10.1097/GRF.0000000000000653.
As fetal gene therapies move from experimental animal models to human in utero phase I clinical trials, there is a need to consider the ethical, legal, and social implications. While fetal gene therapies are attracting more regulatory oversight than previous fetal interventions such as fetal surgery, old sociological questions should be applied to this new context. As health care pathways around fetal therapy are shaped by the ways in which a pregnant person and the fetus are constituted, and as risks and benefits are evaluated, we cannot afford to lose sight of long-term consequences, especially those pertaining to social inclusion.
随着胎儿基因治疗从实验动物模型向人体子宫内 I 期临床试验推进,需要考虑其伦理、法律和社会影响。虽然胎儿基因治疗比以往的胎儿干预措施(如胎儿手术)吸引了更多的监管关注,但旧的社会学问题应该应用于这一新的背景。由于胎儿治疗的医疗保健途径取决于孕妇和胎儿的构成方式,以及风险和收益的评估方式,我们不能忽视长期后果,特别是与社会包容相关的后果。